Spero Therapeutics Inc (2HA.MU)

Compare

0.5750

-0.0710

(-10.99%)

As of 8:02:13 AM GMT+2. Market Open.

We're Keeping An Eye On Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...

Simply Wall St. 6 days ago

SPRO
Q4 2024 Spero Therapeutics Inc Earnings Call

Q4 2024 Spero Therapeutics Inc Earnings Call

Thomson Reuters StreetEvents 7 days ago

SPRO
Spero Therapeutics Inc (SPRO) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Spero Therapeutics Inc (SPRO) reports a significant revenue decline but advances its lead product candidate, tebipenem HBr, in a pivotal Phase 3 trial.

GuruFocus.com 7 days ago

SPRO
Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates

Spero Therapeutics (SPRO) delivered earnings and revenue surprises of -8.57% and 21.32%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?

Zacks 7 days ago

SPRO
Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

Pre-specified interim analysis of Phase 3 PIVOT-PO clinical trial of tebipenem HBr in complicated urinary tract infection (cUTI) is expected to be completed in Q2 2025Company expects to complete analysis of full data set from the Phase 2 study of SPR720 for treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) and determine next steps for the programSPR206, a Phase 2 ready program for hospital and ventilator acquired bacterial pneumonia (HABP/VABP), discontinued following a review

GlobeNewswire 7 days ago

SPRO
Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

CAMBRIDGE, Mass., March 18, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that it will report its financial results for the fourth quarter and full year ended December 31, 2024, and provide a business update, on March 27, 2025. Management will host a conference call and live audio

GlobeNewswire 17 days ago

SPRO
UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero’s Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference bei

GlobeNewswire last month

SPRO
Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO) (Spero), a multi-asset clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial infections, today announced that Esther Rajavelu, Spero’s Interim President and Chief Executive Officer, management will present and will be available for one-on-one meetings at the TD Cowen 45th Annual Health Care Conference bei

GlobeNewswire last month

SPRO
Spero Therapeutics (SPRO) Upgraded to Buy: Here's What You Should Know

Spero Therapeutics (SPRO) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Zacks 2 months ago

SPRO
Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

Esther Rajavelu Appointed Interim President and Chief Executive Officer, Frank Thomas Appointed Chairman of the Board Interim Changes to Leadership Follow the Company’s Response to a Wells Notice from the SEC Relating to Certain Public Disclosures Made in 2022 Phase 3 PIVOT-PO Trial of Tebipenem HBr Reaches Over 60% Enrollment as of December 31, 2024; Remains on Track to Complete Enrollment in 2H 2025 Cash Balance and Cash Runway Guidance Remains into mid-2026 CAMBRIDGE, Mass., Jan. 10, 2025 (GL

GlobeNewswire 2 months ago

SPRO
Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

The rally in ARQT's stock could be attributed to the encouraging regulatory updates seeking label expansion for its sole marketed drug.

Zacks 2 months ago

ARQT

CSTL

CTMX
CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Capricor stock gains 8% upon completing the rolling submission of the BLA for its lead asset, deramiocel, to treat DMD cardiomyopathy in the United States.

Zacks 2 months ago

CAPR

CSTL

SPRO
Neumora Stock Hits Record Low on Depression Drug Study Failure

NMRA stock falls after its experimental depression treatment failed to meet the primary and secondary endpoints in the first of three late-stage studies.

Zacks 2 months ago

NMRA

CSTL

SPRO
EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study

Data from a mid-stage study show that treatment with Edgewise's experimental drug reduces levels of a biomarker related to skeletal muscle damage.

Zacks 3 months ago

EWTX

SPRO
Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Spero Therapeutics (SPRO) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Zacks 3 months ago

SPRO
Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

Shares of QTTB fall after its experimental autoimmune disease drug failed to meet the primary endpoint in a mid-stage study for eczema.

Zacks 3 months ago

CSTL

SPRO

CTMX
JANX Stock Hits Record High on Prostate Cancer Study Data

An early-stage study data shows that treatment with Janux's JANX007 generates deep and durable efficacy responses in heavily pretreated patients with mCRPC.

Zacks 3 months ago

JANX

CSTL

SPRO
PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

Per the terms, PTC will receive $1 billion in upfront payment from Novartis upon the deal's closure. It is also eligible for milestone payments of up to $1.9 billion.

Zacks 3 months ago

PTCT

NVS

SPRO
Grifols Stock Declines After Brookfield Drops Buyout Offer

Brookfield decides to drop its buyout offer for GRFS following discrepancies over the company's valuation.

Zacks 4 months ago

GRFS

BAM

SPRO
JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Following the FDA's approval, Jazz's Ziihera becomes the first dual HER2-targeted bispecific antibody and chemotherapy-free treatment approved for biliary tract cancer.

Zacks 4 months ago

CTMX

SPRO

CSTL

Performance Overview

Return	2HA.MU	S&P 500 (^GSPC)
YTD	-40.17%	-11.81%
1-Year	-64.64%	+0.78%
3-Year	-91.16%	+13.19%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Live

Spero Therapeutics Inc (2HA.MU)

We're Keeping An Eye On Spero Therapeutics' (NASDAQ:SPRO) Cash Burn Rate

Q4 2024 Spero Therapeutics Inc Earnings Call

Spero Therapeutics Inc (SPRO) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges ...

Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates

Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update

Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025

UPDATE – Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference

Spero Therapeutics (SPRO) Upgraded to Buy: Here's What You Should Know

Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes

Here's Why Arcutis Stock More Than Doubled in Market Value in One Year

CAPR Stock Up on Completion of Rolling Submission of DMD Drug BLA

Neumora Stock Hits Record Low on Depression Drug Study Failure

EWTX Stock Rises on Upbeat Data From Rare Muscular Disorder Study

Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

Here's Why Q32 Bio Stock Hit a New Record Low on Wednesday

JANX Stock Hits Record High on Prostate Cancer Study Data

PTCT Stock Soars on Licensing Deal With NVS for Huntington's Therapy

Grifols Stock Declines After Brookfield Drops Buyout Offer

JAZZ Secures FDA Approval for Ziihera in Biliary Tract Cancer

Performance Overview